INTRODUCTION: We analyzed the incidence, risk factors of central nervous system (CNS) relapse, and outcome of CNS involvement in patients with peripheral T-cell lymphomas (PTCL) from the Czech Lymphoma Study Group Registry NiHiL (Clinical Trial gov. NCT03199066). MATERIALS AND METHODS: Out of 1,040 patients with PTCL, we identified 29 patients (2.79%) with CNS involvement: 2 patients with primary CNS T cell lymphoma, 11 patients with CNS and systemic disease at diagnosis, and 16 patients (1.54%) at CNS relapse. The most common histology with CNS disease was PTCL, not otherwise specified. Progression-free survival (PFS) was defined as the time interval from diagnosis to progression or death. PFS-2 was defined as the interval from the date of a new relapse until the next relapse. RESULTS: Patients with testicular involvement received intrathecal prophylaxis with methotrexate. High-dose methotrexate-based treatment was administered in 44.8% of patients with CNS disease. Median follow-up was 71.3 months. The difference between the median PFS of 1,027 patients without initial CNS disease (32.6 months) and 11 patients with initial CNS and systemic disease (4.8 months) was significant (p = 0.04). The difference between the median PFS2 in CNS relapses (10.1 months) and 493 relapses outside of CNS (9.1 months) was not significant (p = 0.6). Risk factors for CNS relapses included the following: involvement of more than one extranodal site (p = 0.008), soft tissue involvement (p = 0.003), testicular involvement (p = 0.046), and the presence of B symptoms (p = 0.035). The difference between the median OS of 1,027 patients without initial CNS disease (46.0 months) and 11 patients with initial CNS and systemic disease (18.2 months) was significant (p = 0.02). The median OS2 in CNS relapses was 11.8 months and that in relapses outside of CNS was 21.3 months. CNS involvement was not associated with a significantly worse OS compared to relapsed/refractory patients without CNS involvement (p = 0.1). CONCLUSIONS: The incidence of CNS disease at the time of diagnosis and at relapse in PTCL is low and usually associated with other systemic involvement. The prognosis of PTCL with initial CNS involvement is significantly worse when compared to patients without CNS disease at diagnosis. The outcome of CNS relapse is comparable with relapsed PTCL outside of CNS. The optimal treatment is not defined yet.

1st Department of Medicine 1st Faculty of Medicine Charles University Prague Czechia

4th Department of Internal Medicine Hematology University Hospital and Faculty of Medicine Hradec Kralove Czechia

Department of Clinical Hematology University Hospital Pilsen Czechia

Department of Haemato Oncology Faculty of Medicine and Dentistry Palacky University Olomouc Czechia

Department of Hemato Oncology University Hospital and Faculty of Medicine Ostrava Czechia

Department of Internal Medicine Hematology 3rd Faculty of Medicine Charles University Prague Czechia

Department of Internal Medicine Hematology and Oncology University Hospital Brno Brno Czechia

Institute of Haematology and Blood Transfusion Prague Czechia

Institute of Pathology and Molecular Medicine University Hospital Motol Prague Czechia

Zobrazit více v PubMed

Zing N, Fischer T, Federico M, Chiattone C, Ferreri AJM. Diagnosis, Prevention and Treatment of Central Nervous System Involvement in Peripheral T-Cell Lymphomas. Crit Rev Oncol Hematol (2021) 167:103496. doi: 10.1016/j.critrevonc.2021.103496 PubMed DOI

Hayabuchi N, Shibamoto Y, Onizuka Y. Primary Central Nervous System Lymphoma in Japan: A Nationwide Survey. Int J Radiat Oncol (1999) 44:265–72. doi: 10.1016/S0360-3016(98)00564-1 PubMed DOI

Lim T, Kim SJ, Kim K, Lee JI, Lim DH, Lee DJ, et al. . Primary CNS Lymphoma Other Than DLBCL: A Descriptive Analysis of Clinical Features and Treatment Outcomes. Ann Hematol (2011) 90:1391–8. doi: 10.1007/s00277-011-1225-0 PubMed DOI PMC

Shenkier TN, Blay JY, O’Neill BP, Poortmans P, Thiel E, Jahnke K, et al. . Primary CNS Lymphoma of T-Cell Origin: A Descriptive Analysis From the International Primary CNS Lymphoma Collaborative Group. J Clin Oncol (2005) 23:2233–9. doi: 10.1200/JCO.2005.07.109 PubMed DOI

Levin N, Soffer D, Grissaru S, Aizikovich N, Gomori JM, Siegal T. Primary T-Cell CNS Lymphoma Presenting With Leptomeningeal Spread and Neurolymphomatosis. J Neurooncol (2008) 90(1):77–83. doi: 10.1007/s11060-008-9633-2 PubMed DOI

Pro B, Perini G. Central Nervous System Prophylaxis in Peripheral T-Cell Lymphoma. Blood (2010) 115(26):5427. doi: 10.1182/blood-2010-02-266890 PubMed DOI

Mak V, Hamm J, Chhanabhai M, Shenkier T, Klasa R, Sehn LH, et al. . Survival of Patients With Peripheral T-Cell Lymphoma After First Relapse or Progression: Spectrum of Disease and Rare Long-Term Survivors. J Clin Oncol (2013) 31(16):1970–6. doi: 10.1200/JCO.2012.44.7524 PubMed DOI

Ellin F, Landström J, Jerkeman M, Relander T. Central Nervous System Relapse in Peripheral T-Cell Lymphomas: A Swedish Lymphoma Registry Study. Blood (2015) 126(1):36–41. doi: 10.1182/blood-2014-12-616961 PubMed DOI

Yi JH, Lee GW, Do YR, Jung HR, Hong JY, Yoon DH, et al. . Multicenter Retrospective Analysis of the Clinicopathologic Features of Monomorphic Epitheliotropic Intestinal T-Cell Lymphoma. Ann Hematol (2019) 98(11):2541–50. doi: 10.1007/s00277-019-03791-y PubMed DOI

Chihara D, Fanale MA, Miranda RN, Noorani M, Westin JR, Nastoupil L, et al. . The Risk of Central Nervous System Relapses in Patients With Peripheral T-Cell Lymphoma. PLoS One (2018) 13(3):e0191461. doi: 10.1371/journal.pone.0191461 PubMed DOI PMC

Gurion R, Mehta N, Migliacci JC, Zelenetz A, Moskowitz A, Lunning M, et al. . Central Nervous System Involvement in T-Cell Lymphoma: A Single Center Experience. Acta Oncol (2016) 55(5):561–6. doi: 10.3109/0284186X.2015.1118656 PubMed DOI PMC

Kim SJ, Oh SY, Hong JY, Chang MH, Lee DH, Huh J, et al. . When do We Need Central Nervous System Prophylaxis in Patients With Extranodal NK/T-Cell Lymphoma, Nasal Type? Ann Oncol (2010) 21(5):1058–63. doi: 10.1093/annonc/mdp412 PubMed DOI

Lebel E, Benshushan S, Paltiel O. From the Skin Straight to the Brain: Rare CNS Recurrence of Cutaneous Anaplastic Large Cell Lymphoma. JCO Oncol Pract (2020) 16(5):247–8. doi: 10.1200/JOP.19.00581 PubMed DOI

Seo HN, Seo JH, Lee CY, Song J, Kim JH, Kim HW. Cutaneous Anaplastic Large T-Cell Lymphoma With Invasion of the Central Nervous System: A Case Report. Brain Tumor Res Treat (2017) 5:45–8. doi: 10.14791/btrt.2017.5.1.45 PubMed DOI PMC

Menon MP, Nicolae A, Meeker H, Raffeld M, Xi L, Jegalian AG, et al. . Primary CNS T-Cell Lymphomas: A Clinical, Morphologic, Immunophenotypic, and Molecular Analysis. Am J Surg Pathol (2015) 39:1719–29. doi: 10.1097/PAS.0000000000000503 PubMed DOI PMC

Lannon M, Lu JQ, Chum M, Wang BH. ALK-Negative CNS Anaplastic Large Cell Lymphoma: Case Report and Review of Literature. Br J Neurosurg (2020), 1–6. doi: 10.1080/02688697.2020.1839630 PubMed DOI

Yim J, Song SG, Kim S, Choi JW, Lee K, Bae JM, et al. . Primary Peripheral Gamma Delta T-Cell Lymphoma of the Central Nervous System: Report of a Case Involving the Intramedullary Spinal Cord and Presenting With Myelopathy. J Pathol Transl Med (2019) 53(1):57–61. doi: 10.4132/jptm.2018.08.21 PubMed DOI PMC

Mooney KL, Choy M, Woodard J, Xian RR, Deal TM, Kendle RF, et al. . Primary Central Nervous System Gamma Delta Cytotoxic T-Cell Lymphoma. J Clin Neurosci (2016) 26:138–40. doi: 10.1016/j.jocn.2015.10.017 PubMed DOI

Kim H, Jeong H, Yamaguchi M, Sohn I, Yoon SE, Byeon S, et al. . Prediction and Prevention of Central Nervous System Relapse in Patients With Extranodal Natural Killer/T-Cell Lymphoma. Blood (2020) 136(22):2548–56. doi: 10.1182/blood.2020005026 PubMed DOI

Sieniawski M, Angamuthu N, Boyd K, Chasty R, Davies J, Forsyth P, et al. . Evaluation of Enteropathy-Associated T-Cell Lymphoma Comparing Standard Therapies With a Novel Regimen Including Autologous Stem Cell Transplantation. Blood (2010) 115(18):3664–70. doi: 10.1182/blood-2009-07-231324 PubMed DOI

Kwong YL, Chan TSY, Tan D, Kim SJ, Poon LM, Mow B, et al. . PD1 Blockade With Pembrolizumab Is Highly Effective in Relapsed or Refractory NK/T-Cell Lymphoma Failing L-Asparaginase. Blood (2017) 129(17):2437–42. doi: 10.1182/blood-2016-12-756841 PubMed DOI

Nevel KS, Pentsova E, Daras M. Clinical Presentation, Treatment, and Outcomes of Patients With Central Nervous System Involvement in Extranodal Natural Killer/T-Cell Lymphoma. Leuk Lymphoma (2019) 60(7):1677–84. doi: 10.1080/10428194.2018.1551541 PubMed DOI PMC

Ferreri AJM, Doorduijn JK, Re A, Cabras MG, Smith J, Ilariucci F, et al. . MATRix-RICE Therapy and Autologous Haematopoietic Stem-Cell Transplantation in Diffuse Large B-Cell Lymphoma With Secondary CNS Involvement (MARIETTA): An International, Single-Arm, Phase 2 Trial. Lancet Haematol (2021) 8: e110–21. doi: 10.1016/S2352-3026(20)30366-5 PubMed DOI PMC

Ferreri AJ, Cwynarski K, Pulczynski E, Ponzoni M, Deckert M, Politi LS, et al. . Chemoimmunotherapy With Methotrexate, Cytarabine, Thiotepa, and Rituximab (MATRix Regimen) in Patients With Primary CNS Lymphoma: Results of the First Randomisation of the International Extranodal Lymphoma Study Group-32 (IELSG32) Phase 2 Trial. Lancet Haematol (2016) 3:e217–27. doi: 10.1016/S2352-3026(16)00036-3 PubMed DOI

Ferreri AJ, Donadoni G, Cabras MG, Patti C, Mian M, Zambello R, et al. . High Doses of Antimetabolites Followed by High-Dose Sequential Chemoimmunotherapy and Autologous Stem-Cell Transplantation in Patients With Systemic B-Cell Lymphoma and Secondary CNS Involvement: Final Results of a Multicenter Phase II Trial. J Clin Oncol (2015) 33(33):3903–10. doi: 10.1200/JCO.2015.61.1236 PubMed DOI

Korfel A, Elter T, Thiel E, Hänel M, Möhle R, Schroers R, et al. . Phase II Study of Central Nervous System (CNS)-Directed Chemotherapy Including High-Dose Chemotherapy With Autologous Stem Cell Transplantation for CNS Relapse of Aggressive Lymphomas. Hematologica (2013) 98(3):364–70. doi: 10.3324/haematol.2012.077917 PubMed DOI PMC

Younes A, Bartlett NL, Leonard JP, Kennedy DA, Lynch CM, Sievers EL, et al. . Brentuximab Vedotin (SGN-35) for Relapsed CD30-Positive Lymphomas. N Engl J Med (2010) 363(19):1812–21. doi: 10.1056/NEJMoa1002965 PubMed DOI

Yi JH, Kim JH, Baek KK, Lim T, Lee DJ, Ahn YC, et al. . Elevated LDH and Paranasal Sinus Involvement are Risk Factors for Central Nervous System Involvement in Patients With Peripheral T-Cell Lymphoma. Ann Oncol (2011) 22(7):1636–43. doi: 10.1093/annonc/mdq645 PubMed DOI PMC

Zucca E, Conconi A, Mughal TI, Sarris AH, Seymour JF, Vitolo U, et al. . Patterns of Outcome and Prognostic Factors in Primary Large-Cell Lymphoma of the Testis in a Survey by the International Extranodal Lymphoma Study Group. J Clin Oncol (2003) 21(1):20–7. doi: 10.1200/JCO.2003.11.141 PubMed DOI

Zobrazit více v PubMed

ClinicalTrials.gov
NCT03199066